ALXN2220-ATTRCM-301: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Brief description of study

We are doing this study to learn more about an experimental drug called ALXN2220 for the proposed treatment of adult patients with ATTR-CM, and to better understand the studied disease and associated health problems.

Experimental means ALXN2220 has not been fully tested in patients with ATTR-CM yet, and it is not approved by any health authority, except for use in research studies like this one.

Clinical Study Identifier: s23-01377

ClinicalTrials.gov Identifier: NCT06183931

Principal Investigator: Jose A Alvarez-Cardona.

Other Investigators: Alex Reyentovich, Jadranka Stojanovska, Maureen Coletta Geary, Maria Alejandra Gonzalez-Duarte Briseno.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies